Odyssey Acquisition News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.12.24	BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission (Businesswire)
17.10.24	BenevolentAI Appoints Kenneth Mulvany as Executive Chairman (Businesswire)
10.10.24	BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024 (Businesswire)
19.09.24	BenevolentAI Interim Results for the Six Months Ended 30 June 2024 (Businesswire)
04.07.24	BenevolentAI: Appointment of Adviser (Businesswire)
03.07.24	BenevolentAI: Leadership Team Change (Businesswire)
25.06.24	BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio (Businesswire)
19.06.24	BenevolentAI CEO to Join Panel at Morgan Stanley 3rd Annual Life Sciences AI Summit (Businesswire)
04.06.24	BenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference (Businesswire)
15.05.24	BenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected (Businesswire)
02.05.24	BenevolentAI: Result of Annual General Meeting (Businesswire)
23.04.24	BenevolentAI Provides an Update on Its Business Priorities (Businesswire)
17.04.24	BenevolentAI: Publication of the Revised Agenda for the 2024 AGM (Businesswire)
15.04.24	Proposed Changes to BenevolentAI’s Board Composition (Businesswire)
25.03.24	BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers (Businesswire)
20.03.24	BenevolentAI Appoints New Chief Technology Officer (Businesswire)
20.03.24	BenevolentAI: Publication of 2023 Annual Report and 2024 AGM Notice (Businesswire)
04.03.24	BenevolentAI: Notice of Preliminary Results (Businesswire)
24.01.24	BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer (Businesswire)
28.12.23	BenevolentAI: Shareholder Letter December 2023 (Businesswire)
21.09.23	BenevolentAI: Directorate Change (Businesswire)
20.09.23	BenevolentAI Signs Strategic Collaboration with Merck (Businesswire)
18.09.23	BenevolentAI Welcomes Christina Busmalis as its New Chief Revenue Officer (Businesswire)
15.09.23	BenevolentAI Notice of Interim Results (Businesswire)
11.09.23	BenevolentAI: Appointment of Catherine Isted, ACMA, as Chief Financial Officer (Businesswire)
31.08.23	BenevolentAI Doses First Participants in Clinical Trial of BEN-8744; Targets PDE10, an AI-derived Novel Target for the Treatment of Ulcerative Colitis (Businesswire)
21.06.23	BenevolentAI: Board Change (Businesswire)
05.06.23	BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies (Businesswire)
31.05.23	New Preclinical Data on AI-Generated Target Identified in BenevolentAI and AstraZeneca Collaboration Presented at ATS 2023 (Businesswire)
25.05.23	BenevolentAI Unveils Strategic Plan to Position the Company for a New Era in AI (Businesswire)
05.04.23	BenevolentAI Announces Top-Line Phase IIa Results for Its Topical pan-Trk Inhibitor BEN-2293 (1%) in Mild-to-Moderate Atopic Dermatitis (Businesswire)
24.03.23	BenevolentAI Announces Publication of Convening Notice for AGM (Businesswire)
06.10.22	BenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca (Businesswire)
27.09.22	BenevolentAI Analyst / Investor Event (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Odyssey Acquisition S.A. Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten